IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

Study Description

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

The aim of the study is to confirm efficacy of treatment for 16 and 24 weeks in chronically infected HCV GT1b treatment naïve patients, including patients with compensated cirrhosis.

Condition or disease	Intervention/treatment	Phase
Hepatitis C, Chronic	Drug: Ribavirin (RBV); Drug: BI 201335 (Faldaprevir); Drug: BI 207127; Drug: Faldaprevir (BI 201335)	Phase 3

Study Design

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	470 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Double
Primary Purpose:	Treatment
Official Title:	A Phase III, Randomized, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination With Faldaprevir and Ribavirin in Treatment-Naive Patients With Chronic Genotype 1 HCV Infection
Study Start Date :	December 2012
Actual Primary Completion Date :	January 2015
Actual Study Completion Date :	January 2015

Arms and Interventions

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: Allocated 24 weeks BI 207127 + BI 201335; 24 weeks of BI 207127 and BI 201335 in combination with Ribavirin	Drug: Ribavirin (RBV); 24 weeks of active RBV; Drug: BI 201335 (Faldaprevir); 24 weeks of BI 201335; Drug: BI 207127; 24 weeks of BI 207127
Experimental: Randomized 16 weeks BI 7127+BI1335 + RBV; 16 weeks of BI 207127 and QD BI 201335 RBV, followed by additional 8 weeks of placebo BI 207127+ placebo BI 201335 in combination with placebo RBV	Drug: BI 201335 (Faldaprevir); 16 weeks of BI 201335 followed by 8 weeks placebo to BI 201335; Drug: Ribavirin (RBV); 16 weeks of Ribavirin followed by 8 weeks of placebo to Ribavirin; Drug: BI 207127; 16 weeks BI 207127 followed by 8 weeks placebo to BI 207127
Experimental: Randomized 24weeks BI 7127+ BI1335 + RBV; 24 weeks of BI 207127and BI 201335 in combination with RBV	Drug: Ribavirin (RBV); 24 weeks of active RBV; Drug: BI 207127; 24 weeks of BI 207127; Drug: Faldaprevir (BI 201335); 24 weeks of 201335

Outcome Measures

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. SVR12 Rates With Historical Control [ Time Frame: 12 Week (post-treatment) ]
   Sustained Virologic Response at Week 12 post-treatment (SVR12): Plasma Hepatitis C Virus ribonucleic acid (HCV RNA) level <25 international units/millilitre (IU/mL) at 12 weeks after End of Treatment (EoT). SVR12, was assessed based on the observed HCV RNA result taken at least 10 weeks after treatment discontinuation. This definition was also applied to patients who discontinued treatment early: if the patient had HCV RNA undetected at least 10 weeks after stopping all treatment, they were considered a responder in the primary analysis. This is the primary analyses of the primary endpoint
2. Comparisons of SVR12 Rates Across Treatment Arms [ Time Frame: 12 Week (post-treatment) ]
   Sustained Virologic Response rates across treatment arms at Week 12 post-treatment (SVR12). This is the secondary analyses of the primary endpoint.

Secondary Outcome Measures :

1. SVR4 [ Time Frame: 4 Week (post-treatment) ]
   Sustained Virologic Response rates across treatment arms at Week 4 post-treatment (SVR4).
2. SVR24 [ Time Frame: 24 Week (post-treatment) ]
   Sustained Virologic Response rates across treatment arms at Week 24 post-treatment (SVR24).

Eligibility Criteria

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria:

• Chronic hepatitis C infection, diagnosed by positive HCV Ab or detectable HCV RNA at screening in addition to at least one of the following:

  1. positive HCV RNA or HCV antibodies at least 6 months prior to screening, or
  2. liver biopsy typical of chronic hepatitis C , or
  3. history of elevated ALT at least 6 months prior to screening.
• HCV infection of sub-GT1b confirmed by genotypic testing at screening

• Treatment naïve defined as:

  1. no prior treatment with any interferon, pegylated interferon, and /or ribavirin and
  2. no prior treatment with at least one dose of any other licensed or investigational antiviral agent for acute or chronic hepatitis C infection
• Plasma HCV RNA > or = 1,000 IU/mL at screening
• Liver biopsy within three years or fibroscan within six months prior to randomization. Patients with compensated liver cirrhosis (score Child-Pugh A) could also be included.
• Age 18 to 75 years

• Female patients with a negative urine pregnancy test (dipstick) at Visit 2 prior to randomization

  1. with documented hysterectomy, or
  2. who have had both ovaries removed, or
  3. with documented tubal ligation, or
  4. who are post-menopausal with last menstrual period at least 12 months prior to screening, or
  5. of childbearing potential with a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 (Visit 2), that agree to use two non-hormonal methods of birth control from the date of screening until months after the last dose of ribavirin. They must not breast-feed at any time from the date of screening until 7 months after the last dose of ribavirin. Medically accepted methods of contraception for females in this trial are diaphragm with spermicide substance, intrauterine devices, cervical caps and condoms.

OR:

Male patients

1. who are documented to be sterile, or
2. who consistently and correctly use a condom while their female partners (if of child-bearing potential) agree to use one of the appropriate medically accepted methods of birth control from the date of screening until 7 months after the last dose of ribavirin, and
3. without pregnant female partners. It is in the responsibility of the male patient to ensure that his partner (or partners) is not pregnant prior to enrolment into the study or becomes pregnant during the treatment and follow-up phase. Female partners of childbearing potential must perform monthly pregnancy tests from the date of screening until 7 months after the last dose of ribavirin (tests will be provided by the sponsor).

Exclusion criteria:

• HCV infection of mixed genotype (1/2, 1/3, and 1/4) diagnosed by genotypic testing at screening.
• HCV subtype 1a, mixed 1a/1b or GT1 undefined
• Evidence of liver disease mainly due to causes other than chronic HCV infection such as autoimmune hepatitis, primary biliary cirrhosis, hemochromatosis or Wilson's disease
• HIV-1 or HIV-2 infection
• Hepatitis B virus (HBV) infection based on presence of HBs-Ag
• Evidence of decompensated liver disease, or history of decompensated liver disease, defined as history of ascites, hepatic encephalopathy, or bleeding esophageal varices,
• International Normalized Ratio (INR) > or =1.7
• Serum albumin < 3.3 g/dL
• Serum total bilirubin >2.0 times the upper limit of normal (ULN) with direct/indirect ratio >1, unless history of Gilbert's disease
• Active or suspected malignancy or history of malignancy within the last 5 years (with the exception of appropriately treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix)
• Patients with ongoing or historical photosensitivity or recurrent rash

Contacts and Locations

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

  Show 101 Study Locations

Sponsors and Collaborators

Boehringer Ingelheim

Investigators

Study Chair:	Boehringer Ingelheim	Boehringer Ingelheim

More Information

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:

Related links 

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Sarrazin C, Castelli F, Andreone P, Buti M, Colombo M, Pol S, Calinas F, Puoti M, Olveira A, Shiffman M, Stern JO, Kukolj G, Roehrle M, Aslanyan S, Deng Q, Vinisko R, Mensa FJ, Nelson DR. HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection. Clin Exp Gastroenterol. 2016 Nov 24;9:351-363. eCollection 2016.

Responsible Party:	Boehringer Ingelheim
ClinicalTrials.gov Identifier:	NCT01732796 History of Changes
Other Study ID Numbers:	1241.20; 2012-003533-41 ( EudraCT Number: EudraCT )
First Posted:	November 26, 2012
Results First Posted:	April 18, 2016
Last Update Posted:	April 18, 2016
Last Verified:	March 2016

Additional relevant MeSH terms:

Hepatitis C; Hepatitis C, Chronic; Hepatitis, Viral, Human; Virus Diseases; Flaviviridae Infections; RNA Virus Infections; Hepatitis; Liver Diseases	Digestive System Diseases; Hepatitis, Chronic; Ribavirin; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Antiviral Agents; Anti-Infective Agents